CA2620294A1 - Therapie genique oculaire utilisant la transfection mediee par avalanche - Google Patents

Therapie genique oculaire utilisant la transfection mediee par avalanche Download PDF

Info

Publication number
CA2620294A1
CA2620294A1 CA002620294A CA2620294A CA2620294A1 CA 2620294 A1 CA2620294 A1 CA 2620294A1 CA 002620294 A CA002620294 A CA 002620294A CA 2620294 A CA2620294 A CA 2620294A CA 2620294 A1 CA2620294 A1 CA 2620294A1
Authority
CA
Canada
Prior art keywords
set forth
cells
tissue
nucleic acid
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002620294A
Other languages
English (en)
Inventor
Thomas W. Chalberg, Jr.
Mark Blumenkranz
Daniel V. Palanker
Alexander Vankov
Philip Huie, Jr.
Michael F. Marmor
Michele P. Calos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Thomas W. Chalberg, Jr.
Mark Blumenkranz
Daniel V. Palanker
Alexander Vankov
Philip Huie, Jr.
Michael F. Marmor
Michele P. Calos
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas W. Chalberg, Jr., Mark Blumenkranz, Daniel V. Palanker, Alexander Vankov, Philip Huie, Jr., Michael F. Marmor, Michele P. Calos, The Board Of Trustees Of The Leland Stanford Junior University filed Critical Thomas W. Chalberg, Jr.
Publication of CA2620294A1 publication Critical patent/CA2620294A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002620294A 2005-08-15 2006-08-15 Therapie genique oculaire utilisant la transfection mediee par avalanche Abandoned CA2620294A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70848605P 2005-08-15 2005-08-15
US60/708,486 2005-08-15
US36098406A 2006-02-22 2006-02-22
US11/360,984 2006-02-22
PCT/US2006/032249 WO2007022403A2 (fr) 2005-08-15 2006-08-15 Therapie genique oculaire utilisant la transfection mediee par avalanche

Publications (1)

Publication Number Publication Date
CA2620294A1 true CA2620294A1 (fr) 2007-02-22

Family

ID=37758427

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002620294A Abandoned CA2620294A1 (fr) 2005-08-15 2006-08-15 Therapie genique oculaire utilisant la transfection mediee par avalanche

Country Status (5)

Country Link
EP (1) EP1924698A4 (fr)
JP (1) JP2009507780A (fr)
AU (1) AU2006279395A1 (fr)
CA (1) CA2620294A1 (fr)
WO (1) WO2007022403A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226790B2 (en) 2011-02-01 2016-01-05 M.O.E. Medical Devices Llc Plasma-assisted skin treatment
US9351790B2 (en) 2011-09-17 2016-05-31 M.O.E. Medical Devices Llc Electrode geometries and method for applying electric field treatment to parts of the body

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101169B2 (en) * 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
WO2009062149A1 (fr) * 2007-11-08 2009-05-14 Creighton University Procédés pour conserver les neurones de l'oreille interne
WO2012086702A1 (fr) * 2010-12-24 2012-06-28 タカラバイオ株式会社 Technique d'introduction de gènes
EP2670477B1 (fr) * 2011-02-01 2015-11-25 Moe Medical Devices LLC Traitement de la peau assisté par plasma
WO2013040542A1 (fr) * 2011-09-17 2013-03-21 Moe Medical Devices Llc Systèmes, procédés et programmes lisibles par machine pour le traitement des onychomycoses assisté par champ électrique et / ou par plasma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226790B2 (en) 2011-02-01 2016-01-05 M.O.E. Medical Devices Llc Plasma-assisted skin treatment
US9351790B2 (en) 2011-09-17 2016-05-31 M.O.E. Medical Devices Llc Electrode geometries and method for applying electric field treatment to parts of the body

Also Published As

Publication number Publication date
EP1924698A4 (fr) 2010-12-15
JP2009507780A (ja) 2009-02-26
WO2007022403A2 (fr) 2007-02-22
WO2007022403A3 (fr) 2010-04-22
AU2006279395A1 (en) 2007-02-22
EP1924698A2 (fr) 2008-05-28

Similar Documents

Publication Publication Date Title
US8101169B2 (en) Ocular gene therapy using avalanche-mediated transfection
KR102218067B1 (ko) Ａａｖ ｓｆｌｔ-1을 사용한 ａｍｄ의 치료
CA2620294A1 (fr) Therapie genique oculaire utilisant la transfection mediee par avalanche
CN108486152A (zh) 转基因猪的培育方法和应用
CN110295149B (zh) 一种突变株3型鸭甲肝病毒ch-p60-117c株及构建方法
White et al. GFP‐centrin as a marker for centriole dynamics in living cells
KR20180099719A (ko) 눈 장애에 대한 유전자 요법
CN110891418B (zh) 对未孵化卵中的禽类胚胎进行性别确定的方法及其用具
CN113512564A (zh) 以iPSC来源的细胞为载体、基因治疗湿性年龄相关性黄斑变性
KR20190042473A (ko) 중증 혈소판 감소 증후군 바이러스 예방 및 치료용 유전자 백신
CN110218732B (zh) 一种非洲猪瘟病毒串联基因、共表达载体、构建方法及应用
CN110607324A (zh) 奶牛溶菌酶基因乳腺特异性表达重组质粒及其构建方法和应用
CN102061310B (zh) 人fhl1c真核表达载体的构建及其应用
CN110295180B (zh) 一种3型鸭甲肝病毒突变基因isa-a117c-c4334a及构建方法
CN110684781B (zh) 一种3型鸭甲肝病毒突变基因isa-a117c-t1142a及构建方法
CN113943749B (zh) 一种基于crispr基因编辑系统提高同源重组效率的方法
CN111500635B (zh) 一种包含携带核酸分子的载体的试剂盒
TW202307213A (zh) 血管收縮素轉化酶ii(ace2)基因轉殖動物及其用途
CN110484546B (zh) 一种3型鸭甲肝病毒突变基因isa-c4334a及构建方法
CN110283835B (zh) 一种3型鸭甲肝病毒突变基因isa-t1142a-c4334a及构建方法
CN110295148A (zh) 一种快速构建3型鸭甲肝病毒反向遗传株的方法
CN102242116B (zh) 细胞肌动蛋白结合蛋白siRNA干扰片段及其融合表达载体和该表达载体的医药用途
CN110283836B (zh) 一种3型鸭甲肝病毒突变基因isa-t1142a及构建方法
CN110283834B (zh) 一种3型鸭甲肝病毒突变基因isa-a117c及构建方法
CN113215116B (zh) 基于朝阳病毒载体的嵌合病毒、疫苗及其应用

Legal Events

Date Code Title Description
FZDE Dead